You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMifepristone
Accession NumberDB00834  (APRD00432)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome [PubChem]. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).

Structure
Thumb
Synonyms
SynonymLanguageCode
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-oneNot AvailableNot Available
CorluxNot AvailableNot Available
MifegyneNot AvailableNot Available
MifeprexNot AvailableNot Available
MifepristonGermanINN
MifepristonaSpanishINN
MifépristoneFrenchINN
MifepristonumLatinINN
RU-486Not AvailableNot Available
RU486Not AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Korlymtablet300 mgoralCorcept Therapeutics Inc2012-02-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
CorluxCorcept Therapeutics Incorporated
MefipilAbbott
MifegyneExelgyn Laboratories
MifeprexDanco Laboratories
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number84371-65-3
WeightAverage: 429.5937
Monoisotopic: 429.266779369
Chemical FormulaC29H35NO2
InChI KeyVKHAHZOOUSRJNA-GCNJZUOMSA-N
InChI
InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
IUPAC Name
(10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1,6-dien-5-one
SMILES
[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassOxosteroids
Direct ParentOxosteroids
Alternative Parents
Substituents
  • 17-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • Substituted aniline
  • Dialkylarylamine
  • Aniline
  • Benzenoid
  • Ynone
  • Monocyclic benzene moiety
  • Tertiary alcohol
  • Cyclic alcohol
  • Cyclic ketone
  • Tertiary amine
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
PharmacodynamicsMifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol.
Mechanism of actionThe anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results. In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.
AbsorptionThe absolute bioavailability of a 20 mg oral dose is 69%
Volume of distributionNot Available
Protein binding98% (bound to plasma proteins, albumin and a 1-acid glycoprotein)
Metabolism

Hepatic. Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from the loss of two methyl groups from position 11 beta; and RU 42 698, which results from terminal hydroxylation of the 17–propynyl chain.

Route of eliminationFecal: 83%; Renal: 9%.
Half life18 hours
ClearanceNot Available
ToxicityNearly all of the women who receive mifepristone will report adverse reactions, and many can be expected to report more than one such reaction. About 90% of patients report adverse reactions following administration of misoprostol on day three of the treatment procedure. Side effects include more heavy bleeding than a heavy menstrual period, abdominal pain, uterine cramping, nausea, vomiting, and diarrhea.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7135
Caco-2 permeable+0.6716
P-glycoprotein substrateSubstrate0.643
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7606
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.8334
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 substrateNon-inhibitor0.6293
CYP450 2D6 substrateInhibitor0.8931
CYP450 2C19 substrateInhibitor0.8994
CYP450 3A4 substrateInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6129
Ames testNon AMES toxic0.856
CarcinogenicityNon-carcinogens0.825
BiodegradationNot ready biodegradable0.9971
Rat acute toxicity2.7705 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9177
hERG inhibition (predictor II)Non-inhibitor0.6879
Pharmacoeconomics
Manufacturers
  • Danco laboratories llc
Packagers
  • Danco Labs LLC
Dosage forms
FormRouteStrength
Tabletoral300 mg
Prices
Unit descriptionCostUnit
Mifeprex 200 mg tablet90.0USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191-196 °CFDA Label
water solubilityPoorly solubleFDA Label
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00336 mg/mLALOGPS
logP5.33ALOGPS
logP5.13ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)12.87ChemAxon
pKa (Strongest Basic)4.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity132.58 m3·mol-1ChemAxon
Polarizability50.71 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra1D NMR
References
Synthesis Reference

Narendra Joshi, Anil Khile, Nitin Pradhan, “Novel polymorph form M of mifepristone and process for its preparation.” U.S. Patent US20070105828, issued May 10, 2007.

US20070105828
General Reference
  1. Fiala C, Gemzel-Danielsson K: Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006 Jul;74(1):66-86. Epub 2006 May 19. Pubmed
  2. Heikinheimo O, Kekkonen R, Lahteenmaki P: The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception. 2003 Dec;68(6):421-6. Pubmed
  3. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM: Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005 May-Jun;11(3):293-307. Epub 2005 Mar 24. Pubmed
  4. Spitz IM, Bardin CW, Benton L, Robbins A: Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998 Apr 30;338(18):1241-7. Pubmed
  5. Piaggio G, von Hertzen H, Heng Z, Bilian X, Cheng L: Meta-analyses of randomized trials comparing different doses of mifepristone in emergency contraception. Contraception. 2003 Dec;68(6):447-52. Pubmed
External Links
ATC CodesG03XB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (46.5 KB)
MSDSDownload (57.1 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolMay increase the serum concentration of CYP2C9 Substrates.
AcetohexamideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Acetylsalicylic acidMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
ado-trastuzumab emtansineMay increase the serum concentration of CYP3A4 Substrates.
AlfentanilMay increase the serum concentration of CYP3A4 Substrates.
AlfuzosinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
AlogliptinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
AlprazolamMay increase the serum concentration of CYP3A4 Substrates.
AmantadineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
AminophyllineMay increase the serum concentration of CYP3A4 Substrates.
AmiodaroneMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
AmitriptylineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
AmlodipineMay increase the serum concentration of CYP3A4 Substrates.
AmoxapineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
AnagrelideMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
ApixabanMay increase the serum concentration of CYP3A4 Substrates.
ApomorphineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
AprepitantMay increase the serum concentration of CYP3A4 Substrates.
ArformoterolMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
AripiprazoleMay increase the serum concentration of CYP3A4 Substrates.
armodafinilMay increase the serum concentration of CYP3A4 Substrates.
Arsenic trioxideMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
ArtemetherMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
AsenapineMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
AtazanavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
AtomoxetineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
AtorvastatinMay increase the serum concentration of CYP3A4 Substrates.
AvanafilMay increase the serum concentration of CYP3A4 Substrates.
AxitinibMay increase the serum concentration of CYP3A4 Substrates.
BedaquilineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
BenzphetamineMay increase the serum concentration of CYP3A4 Substrates.
BisoprololMay increase the serum concentration of CYP3A4 Substrates.
BoceprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
BortezomibMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
BosentanMay decrease the serum concentration of CYP3A4 Substrates.
BosutinibMay increase the serum concentration of CYP3A4 Substrates.
BromocriptineMay increase the serum concentration of CYP3A4 Substrates.
BuforminMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
BuprenorphineMay increase the serum concentration of CYP3A4 Substrates.
BupropionMifepristone may increase the serum concentration of BuPROPion.
BuserelinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
BuspironeMay increase the serum concentration of CYP3A4 Substrates.
CabazitaxelMay increase the serum concentration of CYP3A4 Substrates.
CabozantinibMay increase the serum concentration of CYP3A4 Substrates.
CalcitriolMay increase the serum concentration of CYP3A4 Substrates.
CanagliflozinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
CarbamazepineCYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.
CelecoxibMay increase the serum concentration of CYP2C9 Substrates.
ChlordiazepoxideMay increase the serum concentration of CYP3A4 Substrates.
ChloroquineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
ChlorpromazineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
ChlorpropamideMay increase the serum concentration of CYP2C9 Substrates.
CilostazolMay increase the serum concentration of CYP3A4 Substrates.
CinacalcetMay increase the serum concentration of CYP3A4 Substrates.
CisaprideMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
CitalopramMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
ClarithromycinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
ClidiniumMay increase the serum concentration of CYP3A4 Substrates.
ClomipramineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
ClonazepamMay increase the serum concentration of CYP3A4 Substrates.
ClozapineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
CocaineMay increase the serum concentration of CYP3A4 Substrates.
ColchicineMay increase the serum concentration of CYP3A4 Substrates.
ConivaptanMay increase the serum concentration of CYP3A4 Substrates.
CorticotropinMay diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic).
Cortisone acetateMay diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic).
CrizotinibMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
Cyproterone acetateMay increase the serum concentration of CYP3A4 Substrates.
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DantroleneMay increase the serum concentration of CYP3A4 Substrates.
DarifenacinMay increase the serum concentration of CYP3A4 Substrates.
DarunavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
DasatinibMay increase the serum concentration of CYP3A4 Substrates.
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DegarelixMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
DelavirdineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
DesfluraneMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
DesipramineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
DesogestrelMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
DiazepamMay increase the serum concentration of CYP3A4 Substrates.
DigoxinMay increase the serum concentration of Digoxin.
DihydroergotamineMay increase the serum concentration of Dihydroergotamine.
DihydrotestosteroneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
DiltiazemMay increase the serum concentration of CYP3A4 Substrates.
DisopyramideMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
DocetaxelMay increase the serum concentration of CYP3A4 Substrates.
DofetilideMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
DolasetronMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
DomperidoneMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
DoxazosinMay increase the serum concentration of CYP3A4 Substrates.
DronedaroneMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
DroperidolMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
DrospirenoneMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
EfavirenzMifepristone may increase the serum concentration of Efavirenz.
EletriptanMay increase the serum concentration of CYP3A4 Substrates.
EliglustatMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
EnfluraneMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
EnzalutamideCYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.
EplerenoneMay increase the serum concentration of CYP3A4 Substrates.
Ergoloid mesylateMay increase the serum concentration of CYP3A4 Substrates.
ErgonovineMay increase the serum concentration of CYP3A4 Substrates.
ErgotamineMay increase the serum concentration of Ergotamine.
EribulinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
ErlotinibMay increase the serum concentration of CYP3A4 Substrates.
EscitalopramMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
EszopicloneMay increase the serum concentration of CYP3A4 Substrates.
Ethinyl EstradiolMay diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens).
EthosuximideMay increase the serum concentration of CYP3A4 Substrates.
EthynodiolMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
EtonogestrelMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
EtoposideMay increase the serum concentration of CYP3A4 Substrates.
EverolimusMay increase the serum concentration of CYP3A4 Substrates.
ExenatideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
EzogabineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
FamotidineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
FelbamateMay increase the serum concentration of CYP3A4 Substrates.
FelodipineMay increase the serum concentration of CYP3A4 Substrates.
FentanylMay increase the serum concentration of FentaNYL.
FesoterodineMay increase the serum concentration of CYP3A4 Substrates.
FingolimodMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
FlecainideMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
FluconazoleMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
FludrocortisoneMay diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic).
FluoxetineMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
FlupentixolMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
FlurazepamMay increase the serum concentration of CYP3A4 Substrates.
FlutamideMay increase the serum concentration of CYP3A4 Substrates.
Fluticasone furoateMay increase the serum concentration of CYP3A4 Substrates.
FluvastatinMifepristone may increase the serum concentration of Fluvastatin.
FormoterolMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
FosamprenavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
FosaprepitantMay increase the serum concentration of CYP3A4 Substrates.
FoscarnetMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
FosphenytoinCYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.
Gadofosveset trisodiumMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
GalantamineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
GefitinibMay increase the serum concentration of CYP3A4 Substrates.
GemifloxacinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
GliclazideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
GlimepirideMay increase the serum concentration of CYP2C9 Substrates.
GlipizideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
GliquidoneMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Glucagon recombinantMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
GlyburideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
GoserelinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
GranisetronMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
GuanfacineMay increase the serum concentration of CYP3A4 Substrates.
HaloperidolMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
HistrelinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
HydrocodoneMay increase the serum concentration of CYP3A4 Substrates.
HydroxyzineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
IbandronateMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
IbutilideMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
IloperidoneMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
ImipramineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
IndacaterolMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
IndapamideMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
IndinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
Insulin AspartMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin DetemirMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin GlargineMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin GlulisineMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin LisproMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin RegularMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin, isophaneMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin, porcineMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
IrinotecanMay increase the serum concentration of CYP3A4 Substrates.
IsavuconazoniumMay increase the serum concentration of CYP3A4 Substrates.
IsofluraneMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
Isosorbide DinitrateMay increase the serum concentration of CYP3A4 Substrates.
Isosorbide MononitrateMay increase the serum concentration of CYP3A4 Substrates.
IsradipineMay increase the serum concentration of CYP3A4 Substrates.
ItraconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
IvacaftorMay increase the serum concentration of CYP3A4 Substrates.
IxabepiloneMay increase the serum concentration of CYP3A4 Substrates.
KetamineMay increase the serum concentration of CYP2C9 Substrates.
LapatinibMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
LeuprolideMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
LevomilnacipranMay increase the serum concentration of CYP3A4 Substrates.
LevonorgestrelMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
LinagliptinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
LithiumMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
LomitapideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.
LopinavirMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
LosartanMay increase the serum concentration of CYP2C9 Substrates.
LovastatinMay increase the serum concentration of Lovastatin.
LULICONAZOLEMay increase the serum concentration of CYP3A4 Substrates.
LumefantrineMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
LurasidoneMay increase the serum concentration of CYP3A4 Substrates.
MACITENTANMay increase the serum concentration of CYP3A4 Substrates.
MaprotilineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
MaravirocMay increase the serum concentration of CYP3A4 Substrates.
Medroxyprogesterone AcetateMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
MefloquineMay increase the serum concentration of CYP3A4 Substrates.
MeloxicamMay increase the serum concentration of CYP2C9 Substrates.
MestranolMay increase the serum concentration of CYP2C9 Substrates.
MetforminMay enhance the hypoglycemic effect of Hypoglycemic Agents.
MethadoneMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
MethotrimeprazineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
MethylergometrineMay increase the serum concentration of CYP3A4 Substrates.
MethylprednisoloneMay diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic).
MetoclopramideMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
MidazolamMay increase the serum concentration of CYP3A4 Substrates.
MirabegronMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
MirtazapineMay increase the serum concentration of CYP3A4 Substrates.
MitiglinideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
ModafinilMay increase the serum concentration of CYP3A4 Substrates.
MoexiprilMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
NateglinideMay increase the serum concentration of CYP2C9 Substrates.
NefazodoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
NelfinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
NifedipineMay increase the serum concentration of CYP3A4 Substrates.
NilotinibMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
NimodipineMay increase the serum concentration of CYP3A4 Substrates.
NisoldipineMay increase the serum concentration of CYP3A4 Substrates.
NorelgestrominMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
NorethindroneMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
NorfloxacinMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
NorgestimateMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
NortriptylineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
OctreotideMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
OlanzapineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
OndansetronMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
OxandroloneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
OxycodoneMay increase the serum concentration of CYP3A4 Substrates.
OxytocinMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
PaliperidoneMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
PanobinostatMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
ParoxetineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
PasireotideMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
PazopanibMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
PegvisomantMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
PentamidineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
PerflutrenMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
PhenforminMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
PhenobarbitalCYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.
PhenytoinCYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.
PimozideMifepristone may enhance the QTc-prolonging effect of Pimozide. Mifepristone may increase the serum concentration of Pimozide.
PioglitazoneMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
PipotiazineMay increase the serum concentration of CYP3A4 Substrates.
PiroxicamMay increase the serum concentration of CYP2C9 Substrates.
PomalidomideMay increase the serum concentration of CYP3A4 Substrates.
PosaconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
PraziquantelMay increase the serum concentration of CYP3A4 Substrates.
PrednisoneMay diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic).
PrimaquineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
PrimidoneCYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.
ProcainamideMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
ProcaineMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
PromazineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
PromethazineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
PropafenoneMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
PropofolMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
ProtriptylineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
QuetiapineMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
QuinidineMifepristone may enhance the QTc-prolonging effect of QuiNIDine. Mifepristone may increase the serum concentration of QuiNIDine.
QuinineMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
RanolazineMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
RegorafenibMay increase the serum concentration of CYP3A4 Substrates.
RepaglinideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
RifampicinCYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.
RifapentineCYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.
RilpivirineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
RisperidoneMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
RitonavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
RivaroxabanMay increase the serum concentration of CYP3A4 Substrates.
RosiglitazoneMay increase the serum concentration of CYP2C8 Substrates.
RuxolitinibMay increase the serum concentration of CYP3A4 Substrates.
Salicylate-sodiumMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
SalmeterolMay increase the serum concentration of CYP3A4 Substrates.
SaquinavirMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
SaxagliptinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
SertralineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
SevofluraneMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
SildenafilMay increase the serum concentration of CYP3A4 Substrates.
SilodosinMay increase the serum concentration of CYP3A4 Substrates.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SimeprevirMay increase the serum concentration of CYP3A4 Substrates.
SimvastatinMay increase the serum concentration of Simvastatin.
SirolimusMifepristone may increase the serum concentration of Sirolimus.
SolifenacinMay increase the serum concentration of CYP3A4 Substrates.
SorafenibMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
SotalolMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
SpiramycinMay increase the serum concentration of CYP3A4 Substrates.
SufentanilMay increase the serum concentration of CYP3A4 Substrates.
SulfadiazineMay increase the serum concentration of CYP2C9 Substrates.
SulfamethoxazoleMay increase the serum concentration of CYP2C9 Substrates.
SulfisoxazoleMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
SulodexideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
SunitinibMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
SuvorexantMay increase the serum concentration of CYP3A4 Substrates.
TadalafilMay increase the serum concentration of CYP3A4 Substrates.
TamoxifenMay increase the serum concentration of CYP2C9 Substrates.
TamsulosinMay increase the serum concentration of CYP3A4 Substrates.
TelaprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.
TelavancinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
TelithromycinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
TemsirolimusMay increase the serum concentration of CYP3A4 Substrates.
TeniposideMay increase the serum concentration of CYP3A4 Substrates.
TestosteroneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
TetrabenazineMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
TheophyllineMay increase the serum concentration of CYP3A4 Substrates.
ThioridazineMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
ThiothixeneMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
TiagabineMay increase the serum concentration of CYP3A4 Substrates.
TizanidineMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TofacitinibMay increase the serum concentration of CYP3A4 Substrates.
TolbutamideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
TolterodineMay increase the serum concentration of CYP3A4 Substrates.
TolvaptanMay increase the serum concentration of CYP3A4 Substrates.
TorasemideMay increase the serum concentration of CYP2C9 Substrates.
ToremifeneMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
TrabectedinMay increase the serum concentration of CYP3A4 Substrates.
TramadolMay increase the serum concentration of CYP3A4 Substrates.
TreprostinilMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
TretinoinMay increase the serum concentration of CYP2C8 Substrates.
TriazolamMay increase the serum concentration of CYP3A4 Substrates.
TrimethoprimMay increase the serum concentration of CYP2C9 Substrates.
TrimipramineMay increase the serum concentration of CYP3A4 Substrates.
TriptorelinMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
VandetanibMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
VardenafilMay increase the serum concentration of CYP3A4 Substrates.
VemurafenibMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
VenlafaxineMay increase the serum concentration of CYP3A4 Substrates.
VildagliptinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
VinblastineMay increase the serum concentration of CYP3A4 Substrates.
VincristineMay increase the serum concentration of CYP3A4 Substrates.
VinorelbineMay increase the serum concentration of CYP3A4 Substrates.
VoriconazoleMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
VorinostatMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
ZafirlukastMay increase the serum concentration of CYP2C9 Substrates.
ZiprasidoneMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
ZolpidemMay increase the serum concentration of CYP3A4 Substrates.
ZonisamideMay increase the serum concentration of CYP3A4 Substrates.
ZopicloneMay increase the serum concentration of CYP3A4 Substrates.
ZuclopenthixolMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
Food InteractionsNot Available

Targets

1. Progesterone receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Progesterone receptor P06401 Details

References:

  1. Greb RR, Kiesel L, Selbmann AK, Wehrmann M, Hodgen GD, Goodman AL, Wallwiener D: Disparate actions of mifepristone (RU 486) on glands and stroma in the primate endometrium. Hum Reprod. 1999 Jan;14(1):198-206. Pubmed
  2. Sun M, Zhu G, Zhou L: [Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata] Zhonghua Fu Chan Ke Za Zhi. 1998 Apr;33(4):227-31. Pubmed
  3. Hazra BG, Basu S, Pore VS, Joshi PL, Pal D, Chakrabarti P: Synthesis of 11beta-(4-dimethylaminophenyl)-17beta-hydroxy-17alpha- (3-methyl-1-butynyl)-4, 9-estradien-3-one and 11beta-(4-acetophenyl)- 17beta-hydroxy-17alpha-(3-methyl-1-butynyl)-4, 9-estradien-3-one: two new analogs of mifepristone (RU-486). Steroids. 2000 Mar;65(3):157-62. Pubmed
  4. Gao Y, Cheng L, Liu Y: [Failure of mifepristone induced interruption of pregnancy: point mutation at genetic codon 722 in human progesterone receptor gene] Zhonghua Fu Chan Ke Za Zhi. 1998 Sep;33(9):549-52. Pubmed
  5. Jiang J, Wu R, Wang Z: [Effects of mifepristone on expression of estrogen receptor and progesterone receptor in cultured human eutopic and ectopic endometria] Zhonghua Fu Chan Ke Za Zhi. 2001 Apr;36(4):218-21. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Glucocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Glucocorticoid receptor P04150 Details

References:

  1. LeVan TD, Babin EA, Yamamura HI, Bloom JW: Pharmacological characterization of glucocorticoid receptors in primary human bronchial epithelial cells. Biochem Pharmacol. 1999 May 1;57(9):1003-9. Pubmed
  2. Attardi BJ, Burgenson J, Hild SA, Reel JR: In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88. Pubmed
  3. Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24. Pubmed
  4. Gu G, Hentunen TA, Nars M, Harkonen PL, Vaananen HK: Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis. 2005 May;10(3):583-95. Pubmed
  5. de Pablos RM, Villaran RF, Arguelles S, Herrera AJ, Venero JL, Ayala A, Cano J, Machado A: Stress increases vulnerability to inflammation in the rat prefrontal cortex. J Neurosci. 2006 May 24;26(21):5709-19. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor inducer

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. Pubmed
  2. Lecureur V, Fardel O, Guillouzo A: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 1994 Nov 28;355(2):187-91. Pubmed

2. Multidrug resistance-associated protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance-associated protein 1 P33527 Details

References:

  1. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999 May 19;258(3):513-8. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 29, 2013 15:39